Home › Companies › CGEN

Compugen

Market cap $191M 94.7M shares (vendor count, Nov 18, 2026) × $2.02 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-02

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Rilvegostomig HER2 readout2026Rilvegostomig HER2 readout, 2026, notable
  2. Rilvegostomig ARTEMIDE-01 readout2H 2026Rilvegostomig ARTEMIDE-01 readout, 2H 2026, notable
  3. GS-0321 Ph1 interimLate 2026 / 2027GS-0321 Ph1 interim, Late 2026 / 2027, notable
  4. COM701 interim1Q 2027COM701 interim, 1Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

Unigen

AI-powered computational discovery engine for identifying novel immuno-oncology drug targets by connecting computational prediction, biological validation and clinical learning; has enabled discovery of TIGIT, PVRIG and IL-18BP as clinical-stage drug targets

Targets: TIGIT, PVRIG, IL-18BP

UnigenX

AI-powered discovery engine expansion into tumor-associated antigens for targeted immune activation modalities such as T cell engagers; designed to identify single targets and target pairs to enable more selective immune targeting of tumor cells in immuno-oncology

Capital (as filed)

Cash
$90.6M cash and cash equivalents · Dec 31, 2025 (20-F)
Short-term investments
$45.8M Dec 31, 2025
Operating cash flow
$7.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$118M cash, runway 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Compugen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Compugen Ltd (CGEN) — Scientific Deep Dive for COM701, GS-0321 and the Unigen Pipeline Near-cash EV with partnered Phase 3 royalty and Gilead option, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class.
  2. Watch UPDATE: Compugen (CGEN) - The Coin Is in the Air MAIA-ovarian fully enrolled with Q1 2027 readout locked, cash floor intact at ~$85M EV, but 'totality of the data' wording raises goalpost concerns and the core tension from June remains unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (16)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)